Your browser doesn't support javascript.
loading
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.
Ali, Moiez; Kaltenbrun, Erin; Anderson, Gray R; Stephens, Sarah Jo; Arena, Sabrina; Bardelli, Alberto; Counter, Christopher M; Wood, Kris C.
Afiliação
  • Ali M; Department of Pharmacology and Cancer Biology, Duke University, Durham, North California 27710, USA.
  • Kaltenbrun E; Department of Pharmacology and Cancer Biology, Duke University, Durham, North California 27710, USA.
  • Anderson GR; Department of Pharmacology and Cancer Biology, Duke University, Durham, North California 27710, USA.
  • Stephens SJ; Department of Pharmacology and Cancer Biology, Duke University, Durham, North California 27710, USA.
  • Arena S; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
  • Bardelli A; Candiolo Cancer Institute-FPO, IRCCS, 10060 Candiolo, Torino, Italy.
  • Counter CM; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
  • Wood KC; Candiolo Cancer Institute-FPO, IRCCS, 10060 Candiolo, Torino, Italy.
Nat Commun ; 8: 15617, 2017 06 08.
Article em En | MEDLINE | ID: mdl-28593995
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteínas Proto-Oncogênicas p21(ras) / Resistencia a Medicamentos Antineoplásicos / Cetuximab / Antineoplásicos Imunológicos Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteínas Proto-Oncogênicas p21(ras) / Resistencia a Medicamentos Antineoplásicos / Cetuximab / Antineoplásicos Imunológicos Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article